Cargando…

Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications

The ATP-binding cassette transporter G2 (ABCG2; also known as breast cancer resistance protein, BCRP) has been suggested to be involved in clinical multidrug resistance (MDR) in cancer like other ABC transporters such as ABCB1 (P-glycoprotein). As an efflux pump exhibiting a broad substrate specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toyoda, Yu, Takada, Tappei, Suzuki, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411714/ https://www.ncbi.nlm.nih.gov/pubmed/30890942 http://dx.doi.org/10.3389/fphar.2019.00208

Ejemplares similares

Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations
por: Miyata, Hiroshi, et al.
Publicado: (2016)

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
por: Toyoda, Yu, et al.
Publicado: (2019)

ABCG5 and ABCG8 Are Involved in Vitamin K Transport
por: Matsuo, Michinori, et al.
Publicado: (2023)

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout
por: Toyoda, Yu, et al.
Publicado: (2021)

Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort
por: Toyoda, Yu, et al.
Publicado: (2019)

Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis
por: Toyoda, Yu, et al.
Publicado: (2016)

Spontaneous Production of Glutathione-Conjugated Forms of 1,2-Dichloropropane: Comparative Study on Metabolic Activation Processes of Dihaloalkanes Associated with Occupational Cholangiocarcinoma
por: Toyoda, Yu, et al.
Publicado: (2017)

Inhibition of post-translational N-glycosylation by HRD1 that controls the fate of ABCG5/8 transporter
por: Suzuki, Shingo, et al.
Publicado: (2014)

Immunohistochemical and in situ hybridization study of urate transporters GLUT9/URATv1, ABCG2, and URAT1 in the murine brain
por: Tomioka, Naoko H., et al.
Publicado: (2016)

Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet
por: Toyoda, Yu, et al.
Publicado: (2019)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021)

Clinical and Molecular Evidence of ABCC11 Protein Expression in Axillary Apocrine Glands of Patients with Axillary Osmidrosis
por: Toyoda, Yu, et al.
Publicado: (2017)

Multiple common and rare variants of ABCG2 cause gout
por: Higashino, Toshihide, et al.
Publicado: (2017)

OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts
por: Toyoda, Yu, et al.
Publicado: (2022)

Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition
por: Toyoda, Yu, et al.
Publicado: (2016)

ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure
por: El Biali, Myriam, et al.
Publicado: (2021)

Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging
por: Qawasmi, Israa, et al.
Publicado: (2014)

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
por: Gao, Hai-Ling, et al.
Publicado: (2023)

Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2
por: Matsuo, Hirotaka, et al.
Publicado: (2016)

Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients
por: Nakashima, Akio, et al.
Publicado: (2020)

SVCT2/SLC23A2 is a sodium-dependent urate transporter: functional properties and practical application
por: Toyoda, Yu, et al.
Publicado: (2023)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin
por: Zhang, Jingyao, et al.
Publicado: (2018)

Y(6), an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance
por: Zhao, Rui-Qiang, et al.
Publicado: (2019)

Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2
por: Taniguchi, Tetsuya, et al.
Publicado: (2021)

Inhibitory effect of Citrus flavonoids on the in vitro transport activity of human urate transporter 1 (URAT1/SLC22A12), a renal re-absorber of urate
por: Toyoda, Yu, et al.
Publicado: (2020)

ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment
por: Zou, Houwen, et al.
Publicado: (2021)

Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-absorber
por: Saito, Hiroki, et al.
Publicado: (2020)

Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: In Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary Flavonoids
por: Saito, Hiroki, et al.
Publicado: (2020)

Identification of Inhibitory Activities of Dietary Flavonoids against URAT1, a Renal Urate Re-Absorber: In Vitro Screening and Fractional Approach Focused on Rooibos Leaves
por: Toyoda, Yu, et al.
Publicado: (2022)

Common dysfunctional variants in ABCG2 are a major cause of early-onset gout
por: Matsuo, Hirotaka, et al.
Publicado: (2013)

Identification of hepatic NPC1L1 as an NAFLD risk factor evidenced by ezetimibe‐mediated steatosis prevention and recovery
por: Toyoda, Yu, et al.
Publicado: (2019)

ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity
por: Gauthier, Charlotte, et al.
Publicado: (2013)

Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2
por: Ripperger, Anne, et al.
Publicado: (2018)

Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors
por: Nakayama, Akiyoshi, et al.
Publicado: (2014)

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
por: Sun, Fengjun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lcu20hbj7fp954qbgdlfm4bfra